Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Welcome to this next fireside chat with Exelixis. With us today, we have Mike Morrissey, President and CEO.
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but introduce the first immunotherapy approach in refractory mCRC, despite notable toxicity concerns. EXEL's pipeline strength is buoyed by zanzalintinib, but real-world adoption and broader success remain uncertain due to tolerability and trial design limitations.
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript
Exelixis, Inc. ( EXEL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor Relations Michael Morrissey - CEO, President & Director Christopher Senner - Executive VP & CFO Dana Aftab - Executive Vice President of Research & Development P. Haley - Executive Vice President of Commercial Conference Call Participants Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Anastasia Parafestas - Jefferies LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.47 per share a year ago.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
